Clemizole - University of California at San Fransisco/Epygenix Therapeutics

Drug Profile

Clemizole - University of California at San Fransisco/Epygenix Therapeutics

Alternative Names: EPX 100

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at San Francisco
  • Developer Epygenix Therapeutics; University of California at San Francisco
  • Class Antiallergics; Antiepileptic drugs; Antihistamines; Benzimidazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Dravet syndrome

Most Recent Events

  • 03 May 2017 Clemizole - University of California at San Fransisco/Epygenix Therapeutics is available for licensing as of 03 May 2017. http://epygenix.com/
  • 03 May 2017 Chemical structure information added
  • 25 Apr 2017 Clemizole receives Orphan Drug status for Dravet syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top